IDH1 and glioma: Our results, which indicate that we could use miRNAs as tools for monitoring patients with IDH1/2-mutated gliomas, are consistent with the study of Chen and co-workers, based on another miRNA, mir-720, assayed on 122 patients with glioma (Stage I: 20; Stage II: 17; Stage III: 35; and Stage IV: 50, according to the WHO 2016 classification).